LakeShore Biopharma (LSBCF)
OTHER OTC:LSBCF
Top Page
LakeShore Biopharma
(OTC:LSBCF)
Select Model
Select Model
Rating:40Underperform
Price Target:
$0.07
▼(-92.12% Downside)
Action:ReiteratedDate:03/07/26
The score is primarily constrained by weak financial performance—ongoing losses and negative operating/free cash flows—combined with a very bearish technical setup (price well below major moving averages and negative MACD). Valuation offers limited support because the company is unprofitable (negative P/E) and no dividend yield is provided.
Positive Factors
High gross margins
Sustained gross margins above 75% indicate strong unit economics and pricing power for core products. This margin buffer supports long-term R&D and commercialization even if operating costs fluctuate, enabling a path to profitability if operating leverage improves.
Negative Factors
Persistent operating losses and cash burn
Sustained negative EBIT and operating/free cash flows erode liquidity and require recurrent financing or asset sales. Over months this constrains investment in R&D and commercialization, raises dilution/default risk, and weakens ability to withstand legal or market shocks without external funding.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained gross margins above 75% indicate strong unit economics and pricing power for core products. This margin buffer supports long-term R&D and commercialization even if operating costs fluctuate, enabling a path to profitability if operating leverage improves.
Read all positive factors
LakeShore Biopharma (LSBCF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.88M
Dividend YieldN/A
Average Volume (3M)5.12K
Price to Earnings (P/E)―
Beta (1Y)1.43
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees758
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,212,692
10 Day Avg. Volume4,144
30 Day Avg. Volume5,120
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)3.80
Price to Sales (P/S)3.09
P/FCF Ratio-13.69
Enterprise Value/Market Cap140.75
Enterprise Value/Revenue0.70
Enterprise Value/Gross Profit1.04
Enterprise Value/Ebitda-1.29
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)36.7
Revenue Forecast (FY)$1.80B
LakeShore Biopharma Business Overview & Revenue Model
Company Description
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA imm...
How the Company Makes Money
null...
LakeShore Biopharma Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
40
Negative
Cash Flow
35
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Jun 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 577.33M | 614.96M | 573.42M | 687.20M | 502.95M | 257.02M |
| Gross Profit | 389.12M | 507.19M | 455.73M | 533.84M | 381.49M | 197.36M |
| EBITDA | -314.29M | -48.54M | -368.66M | -76.80M | -67.20M | -116.78M |
| Net Income | -433.70M | -99.98M | -433.46M | -145.48M | -236.67M | -191.83M |
Balance Sheet | ||||||
| Total Assets | 1.51B | 1.37B | 1.51B | 1.72B | 201.03M | 91.37K |
| Cash, Cash Equivalents and Short-Term Investments | 246.35M | 28.08M | 246.35M | 370.11M | 271.07M | 390.46M |
| Total Debt | 424.46M | 414.40M | 424.46M | 498.63M | 380.59M | 18.70M |
| Total Liabilities | 927.82M | 867.91M | 927.82M | 991.30M | 20.35M | 70.01K |
| Stockholders Equity | 585.21M | 499.75M | 585.21M | 728.45M | 671.25M | 776.60M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -138.84M | -339.48M | -239.52M | -299.55M | -351.49M |
| Operating Cash Flow | 0.00 | -120.98M | -295.23M | -182.47M | -613.23K | -246.61M |
| Investing Cash Flow | 0.00 | -17.01M | -44.25M | -56.98M | -298.92M | -104.24M |
| Financing Cash Flow | 0.00 | -3.58M | 205.26M | 317.45M | 364.56M | 739.26M |
LakeShore Biopharma Technical Analysis
Negative
0.85
Price Trends
0.19
Negative
0.52
Negative
0.68
Negative
Market Momentum
-0.03
Negative
32.68
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LSBCF, the sentiment is Negative. The current price of 0.85 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.19, and above the 200-day MA of 0.68, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 32.68 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LSBCF.
LakeShore Biopharma Risk Analysis
LakeShore Biopharma disclosed 100 risk factors in its most recent earnings report. LakeShore Biopharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
LakeShore Biopharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $54.40M | -0.82 | -62.53% | ― | ― | 35.80% | |
56 Neutral | $80.72M | -2.08 | -291.42% | ― | ― | 61.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $102.80M | -3.01 | -718.54% | ― | ― | 25.08% | |
43 Neutral | $25.69M | -6.90 | -108.76% | ― | -100.00% | 33.44% | |
40 Underperform | $2.88M | ― | ― | ― | ― | ― |
* Healthcare Sector Average
LSBCF
LakeShore Biopharma
0.07
-1.66
-95.94%
KZR
Kezar Life Sciences
7.38
3.28
80.00%
XCUR
Exicure
4.03
-7.47
-64.96%
PYPD
PolyPid
4.23
1.72
68.53%
RANI
Rani Therapeutics Holdings
0.83
-0.43
-34.05%
LakeShore Biopharma Corporate Events
LakeShore Biopharma Weighs Cut‑Price Take‑Private Bid After RMB576.5 Million Arbitration Hit
Mar 25, 2026
LakeShore Biopharma said on March 25, 2026 that a special committee of its board received a revised preliminary non‑binding proposal from Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. to acquire all outstanding ordinary shares they an...
LakeShore Biopharma’s Buyer Group Challenges Merger After RMB576.5 Million Arbitral Hit, Forcing EGM Delay
Feb 6, 2026
On February 6, 2026, LakeShore Biopharma disclosed that the buyer group behind its previously announced going-private deal at $0.90 per share has notified the company that recent arbitral awards totaling about RMB576.5 million in financial liabili...
LakeShore Biopharma Faces Disputed RMB500 Million Arbitration Awards Amid Fraud Investigation
Jan 29, 2026
On January 21 and 22, 2026, LakeShore Biopharma reported that arbitral awards issued by the Kaifeng Arbitration Commission require its affiliated entities, Liaoning Yisheng Biopharma and Beijing Yisheng Biotechnology, to pay counterparties a combi...
LakeShore Biopharma Sets February 12 EGM to Approve Going-Private Merger
Jan 20, 2026
On January 20, 2026, LakeShore Biopharma announced it has called an extraordinary general meeting of shareholders for February 12, 2026 in Beijing to vote on authorizing and approving its previously announced merger agreement with Oceanpine Skylin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.